BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND MYD88, Q99836, MYD88D, 4615 AND Prognosis
10 results:

  • 1. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
    Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
    J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
    Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
    [No Abstract]    [Full Text] [Related]  

  • 3. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the myd88-dependent NF-κB signaling pathway.
    Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
    J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Expression of lnc-myd88 and its relationship with the prognosis of patients with epithelial ovarian cancer].
    Zhu Y; Huang JM; Zhang GN; Li JM; Huang J
    Zhonghua Fu Chan Ke Za Zhi; 2022 Feb; 57(2):117-124. PubMed ID: 35184472
    [No Abstract]    [Full Text] [Related]  

  • 5. Morphologic Patterns and the Correlation With myd88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
    Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
    Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors.
    Alvero AB; Montagna MK; Sumi NJ; Joo WD; Graham E; Mor G
    Oncotarget; 2014 Sep; 5(18):8703-15. PubMed ID: 25237928
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The myd88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
    d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
    PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Expression and significance of the TLR4/myd88 signaling pathway in ovarian epithelial cancers.
    Kim KH; Jo MS; Suh DS; Yoon MS; Shin DH; Lee JH; Choi KU
    World J Surg Oncol; 2012 Sep; 10():193. PubMed ID: 22985132
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.